MedTrace Logo

A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD

NCT01157715 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2014-11-06

No results posted yet for this study

Summary

This study is designed to access the safety and efficacy of multiple injections of KH902 at variable dosing regimens in patients with CNV due to neovascular AMD.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

BIOLOGICAL

intravitreal injection of KH902

Sponsors & Collaborators

  • Beijing DMS Pharma Ltd.

    collaborator UNKNOWN

  • The Digital Angiography Reading Center (DARC)

    collaborator UNKNOWN

  • Chengdu Kanghong Biotech Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xiaoxin Li, MD, Prof. · Peking University People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2012-01-31
Completion
2012-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01157715 on ClinicalTrials.gov